Zura Bio Ltd - 8-K Filing

Zura Bio discontinues tibulizumab (ZB-106) development in hidradenitis suppurativa after Phase 2 TibuSHIELD study failed to meet primary and key secondary endpoints. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 9, 2026, 12:07 UTC

Tickers: $ZURA

Read the full article at SEC EDGAR

Part of the story Gossamer Bio, Inc. - 8-K Filing (13 articles)

More Regulatory news

OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC